CDH1 and cancer: Based on CRISPR knockout data, genomic biomarkers and patient data43, TBCD, KLF5 and SOX9 are also predicted to be promising therapeutic targets in CRC, as are CCND1, CDH1, MYC and POU5F1B in many different types of cancer (Supplementary Table 11).